We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Aquestive Therapeutics Inc | NASDAQ:AQST | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.085 | -2.53% | 3.28 | 3.25 | 3.28 | 3.4099 | 3.205 | 3.40 | 1,679,513 | 00:58:51 |
Delaware | 001-38599 | 82-3827296 | ||||||
(State or Other Jurisdiction of Incorporation or Organization)
|
(Commission File Number) | (I.R.S. Employer Identification No.) |
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||||||
Common Stock, par value $0.001 per share
|
AQST
|
Nasdaq Global Market
|
Exhibit Number | Description | |||||||
Press Release, dated July 19, 2021, the U.S. Food and Drug Administration has accepted for filing the resubmission of the New Drug Application for Libervant™ (diazepam) Buccal Film for the management of seizure clusters.
|
Dated: July 19, 2021 | Aquestive Therapeutics, Inc. | ||||||||||
By: | /s/ A. Ernest Toth, Jr. | ||||||||||
Name:
|
A. Ernest Toth, Jr. | ||||||||||
Title:
|
Chief Financial Officer | ||||||||||
(Principal Financial Officer) |
1 Year Aquestive Therapeutics Chart |
1 Month Aquestive Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions